ANI Pharmaceuticals Posts Q3 Revenue of $227.8M, 53.6% YoY Growth, Raises Full-Year Guidance

ANI Pharmaceuticals reported Q3 CY2025 results with revenue of $227.8 million, up 53.6% YoY, and non-GAAP profit of $2.04 per share, 15.2% above analysts' estimates. The company lifted its revenue guidance for the full year to $863.5 million and raised its full-year adjusted EPS guidance to $7.51. ANI Pharmaceuticals' long-term sales performance has grown at a 32.9% compounded annual growth rate over the last five years, beating the average healthcare company.